30,464 Shares in Structure Therapeutics Inc. (NASDAQ:GPCR) Acquired by GSA Capital Partners LLP

GSA Capital Partners LLP acquired a new position in shares of Structure Therapeutics Inc. (NASDAQ:GPCR) in the third quarter, HoldingsChannel.com reports. The firm acquired 30,464 shares of the company’s stock, valued at approximately $1,337,000.

Several other large investors have also recently added to or reduced their stakes in the stock. Assetmark Inc. grew its position in shares of Structure Therapeutics by 120.0% during the third quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock worth $58,000 after acquiring an additional 719 shares during the last quarter. Janney Capital Management LLC bought a new position in Structure Therapeutics in the 3rd quarter worth about $290,000. China Universal Asset Management Co. Ltd. increased its stake in shares of Structure Therapeutics by 99.2% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,460 shares of the company’s stock valued at $503,000 after purchasing an additional 5,707 shares during the period. abrdn plc raised its holdings in shares of Structure Therapeutics by 132.7% during the third quarter. abrdn plc now owns 217,083 shares of the company’s stock valued at $9,528,000 after buying an additional 123,789 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Structure Therapeutics by 60.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,784 shares of the company’s stock worth $158,000 after buying an additional 1,420 shares during the period. 91.78% of the stock is owned by institutional investors and hedge funds.

Structure Therapeutics Stock Performance

Shares of Structure Therapeutics stock opened at $36.37 on Thursday. The business has a fifty day simple moving average of $39.48 and a 200-day simple moving average of $39.87. Structure Therapeutics Inc. has a fifty-two week low of $26.61 and a fifty-two week high of $66.38.

Wall Street Analysts Forecast Growth

GPCR has been the subject of a number of analyst reports. Morgan Stanley assumed coverage on Structure Therapeutics in a research report on Monday, September 23rd. They set an “overweight” rating and a $118.00 price target for the company. Cantor Fitzgerald reiterated an “overweight” rating and issued a $65.00 target price on shares of Structure Therapeutics in a research report on Monday, September 23rd. Finally, JMP Securities dropped their price target on shares of Structure Therapeutics from $91.00 to $86.00 and set a “market outperform” rating on the stock in a research report on Friday, August 9th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Structure Therapeutics currently has an average rating of “Buy” and a consensus target price of $86.80.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.